Obesity Care Continuum (OCC) Commends Food and Drug Administration (FDA) for their Continued Proactive Support and Approval of New Obesity Treatments
Please Note: As of February 2020, the Food and Drug Administration has issued a voluntary withdrawal of Belviq, Belviq XR (lorcaserin) from the U.S. market, as a safety clinical trial has shown an increased occurrence of cancer. Patients currently taking Belviq have been advised to stop taking the medication and speak with their healthcare provider
Read Article